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Reverse transcription (RT)-PCR, the principal diagnos-
tic method applied in the worldwide struggle against
COVID-19, is capable of detecting a single molecule of
a viral genome. Correctly designed and practiced RT-
PCR assays for SARS-CoV-2 should not cross-react
with similar but distinct viral pathogens, such as the
coronaviruses associated with the common cold, and
should perform with very high analytical sensitivity.
This analytical performance is predicated on the ability
of the method to detect the presence of the selected nu-
cleic acid target, without detection of a false positive
signal.
Unlike many other diagnostic methods, such as
ELISA, there should be no “blank” signal in RT-PCR
diagnosis of SARS-CoV-2. False positive results may oc-
cur during testing, but should not be considered as a
background signal or factored into specificity calcula-
tions. Like false negative results, it is incumbent on lab-
oratory practitioners to be wary of, and monitor for,
false positives. The handful of reports of “background”
SARS-CoV-2 signal (1, 2 ) are unlikely to be due to
primer artifacts or cross reactivity with other pathogens,
or human template, given that the assays in question are
referenced by the World Health Organization (3 ) and
have been used across the globe without such observa-
tion. The only practical or technical source of so-called
background for an optimally designed SARS-CoV-2
diagnostic assay is contamination, which is the main
source of false positives when conducting any PCR test.
There are 2 principal contamination routes: cross-
contamination between specimens or synthetically de-
rived target nucleic acids. Cross-contamination from a
positive clinical sample to a negative one can occur dur-
ing specimen sampling, handling, processing, or analy-
sis. While this risk is substantial for SARS-CoV-2 due
to potentially high viral loads, it is not background but
instead a variable technical artifact.
Synthetically derived PCR amplicon contamination
can arise from the billions of copies of the molecule of
interest generated in the course of a PCR assay.
Without proper care, these reaction products can con-
taminate samples or reagents, becoming false positives
in subsequent tests. PCR practitioners have long known
of the risk of carry-over contamination and have devised
procedures and laboratory measures to minimize it (4,
5 ). Yet poor understanding of this artifact has led to er-
roneous, and sometimes tragic, claims such as reported
false evidence linking measles, mumps, and rubella
(MMR) vaccine with autism (6 ).
There is another source of synthetically derived
contamination that may be particularly relevant to
SARS-CoV-2 testing. A common practice for PCR
assay development is for the developer to commission
the synthesis of the intended DNA target, using
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phosphoramadite chemistry, which is a globally estab-
lished process offered by a number of manufacturers, as
a positive control. The synthesis of these gene fragments
is typically at nanomole scale and will produce in excess
of a thousand trillion (1015) copies of single stranded
DNA. It is an essential practice to assure that this con-
trol template is made at different sites, usually from al-
ternate vendors, from those sites making the other PCR
reagents, to avoid this major potential source of contam-
ination. However, as the number of laboratories
developing assays and positive control materials for the
global SARS-CoV-2 pandemic is unprecedented, select-
ing different vendors may no longer prevent this source
of contamination.
There are already examples of such assay-derived
contamination occurring (7 ) that has hampered the di-
agnostic response to COVID-19 (8 ), with RT-PCR
reagents becoming contaminated regardless of whether
they are used to detect SARS-Cov-2 (Fig. 1). This level
of production of synthetic template has the potential to
not only generate false positives and reduce the sensitiv-
ity of our principal diagnostic method, but it may also
limit other areas of research such as measuring viral
spread using environmental sources such as wastewater
(9 ).
With the worldwide application of RT-PCR to a
handful of the same conserved viral genes, we fear that a
quotidian source of contamination of SARS-CoV-2
Box 1 How to be confident your SARS-CoV-2 results are not corrupted with contamination
Test for it
• Assume reagents may contain contamination. Quality control reagents prior to their use (primers, probes, PCR mastermix,
water) using multiple negative control replicates alongside a positive control. Ten negative controls in a 96-well plate rep-
resents a practical number; however, larger numbers of replicates will better assure confidence in ruling out low-level con-
tamination, which can appear both stochastically and infrequently.
• Aliquot reagents for single time use, especially nuclease-free water.
• Implement control procedures that include extraction blanks containing carrier RNA; the latter (present in negative patient
extracts) is important for measuring low-level contamination. Consider using multiple extraction blanks distributed among
sample reactions to detect low-level contamination.
• Further information on the precise source of contamination can be provided by including reverse transcription negative
reactions; this will confirm DNA and not viral RNA as the source.
Apply caution when results are close to the limit of detection of assay
• Beware of large numbers of results with high Cq values near the assay limit of detection.
• Consider the pattern of results. If low signal positives are not randomly distributed (e.g., if they occur adjacent to a high ti-
ter sample), this suggests sample cross-contamination. Consider repeating such low positive samples.
• Consider influences of preanalysis and sample cross-contamination.
• If possible, test for more than one SARS-CoV-2 target gene.
Take preventive measures
• Physically separate PCR setup and sample handling steps (and equipment) from those used for PCR analysis. It is absolutely
crucial to use pre- and post-PCR rooms as well as unidirectional transit from pre to post-PCR laboratories
• Consider steps during preparation that may lead to contamination through aerosol production: pipetting (high throughput),
centrifuges, etc. may lead to aerosols that can result in cross-contamination.
Get rid of it
• Discard all reagents linked to contaminated reactions. While systematic evaluation may determine which reaction compo-
nent is the culprit, it is recommended to start from scratch and replace all the reagents.
• Deep clean the laboratory using proven solutions that destroy nucleic acids (e.g., bleach and UV) on a daily basis
• If contamination persists, users may need to halt clinical testing and redesign the assay to different part of the pathogen’s
genome.
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diagnostic RT-PCR is being experienced, yet over-
looked. Some of the laboratories applying the procedure
may be unaware that such contamination may compro-
mise the accuracy of the very methods we are currently
depending on to monitor this pandemic. In response,
there are basic steps users can apply to monitor and re-
duce contamination (Box 1). While synthesis of molec-
ular targets will remain an important tool for assay
development, vendors and users may ask whether, given
the vast amount of SARS-CoV-2 sequence that has al-
ready been made, it is possible for a template to be
obtained using collaborative or commercial sources
other than chemical synthesis. Should synthesis still be
required, vendors could explore solutions, such as incor-
porating “watermarks” (10 ) into the synthesized mate-
rial, to allow these sources of positive signal to be
distinguished from actual SAR-CoV-2 RNA.
A timely global response to this pandemic has been
made possible by RT-PCR. To fully exploit the sensitiv-
ity of this method, we must be cognizant of and rigor-
ously test for potential contamination of reagents. As
with the pandemic, knowledge of and testing for con-
tamination will prevent it from spreading. Moreover,
lessons learned with respect to this emerging global chal-
lenge of reagent contamination should be taken into
consideration in preparedness and response planning for
future pandemics.
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Fig. 1. RNA extracts from 60 SARS-CoV-2 negative clinical samples (nasopharyngeal swabs and aspirates) and a positive control
[RNA transcript of the SARS-CoV-2 nucleocapsid (N) gene] were amplified in parallel in 2 multiplexed reactions: a) amplification
plot showing SARS-CoV-2 fluorescence from a duplex reaction that contains SARS-CoV-2 and RNaseP primers and probes. b) am-
plification plot of SARS-CoV-2 fluorescence in a triplex PCR assay including the targets SARS-CoV-2, RNaseP, and an internal
spike positive control (phocine distemper virus, PDV). This illustrates SARS-CoV-2 target contamination from a non-SARS-CoV-2
assay, in this case PDV: half of the negative patient samples now test positive for SARS-CoV-2. The real-time amplification plots
for SARS-CoV-2 (N2) were performed on a QuantStudio 5 thermal cycler (Thermo Fisher) using the One Step PrimeScript III RT-
PCR Kit (Takara). x axis ¼ PCR cycles, y axis ¼ fluorescence, curved lines ¼ plots of amplified SARS-CoV-2 target.
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